Publication of a new article in the peer-reviewed journal "Genes and Cancer"
We are very pleased to inform you about the publication of a new scientific paper in the peer-reviewed journal "Genes and Cancer" as a "Research Perspective". Article is entitled: Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines.
In the context of the increasing interest of neoantigens-based cancer vaccines in the field of immuno-oncology, the article describes the importance of vaccine platforms to induce protective immunity, and in particular, the competitive advantages of our technology (PDC*vac platform) in the field. Illustrated by experimental data we propose to use PDC*line cells to develop neoantigen-based cancer vaccines for the treatment of patients in combination with anti-PD1 treatment.
In recent years, immunotherapy has finally found its place in the anti-cancer therapeutic arsenal, even becoming standard of care as first line treatment for metastatic forms. The clinical benefit provided by checkpoint blockers such as anti- PD-1/PD-L1 in many cancers revolutionized the field. However, too many patients remain refractory to these treatments due to weak baseline anti-cancer immunity. There is therefore a need to boost the frequency and function of patients’ cytotoxic CD8+ cellular effectors by targeting immunogenic and tumor-restricted antigens, such as neoantigens using an efficient vaccination platform. Dendritic cells (DC) are the most powerful immune cell subset for triggering cellular immune response. However, autologous DC-based vaccines display several limitations, such as the lack of reproducibility and the limited number of cells that can be manufactured. Here we discuss the advantages of a new therapeutic vaccine based on an allogeneic Plasmacytoid DC cell line, which is easy to produce and represents a powerful platform for priming and expanding anti-neoantigen cytotoxic CD8+ T-cells.
Please find below the link for the full article in PDF version:
Hannani, Genes & Cancer 2023_Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines.pdf